Urologists were concerned about the effect of 5ARIs on masking prostate cancer when monitoring PSA levels, highlighting a need to provide additional data and education on the latest evidence, which would allow urologists to make informed choices when treating and monitoring patients with LUTS/BPE receiving 5ARIs [24, 29–34]. Here, KLK3 is linked to prostate carcinoma.